Share this story:

Sernova Medical Advances Gain Media Attention



Sernova Corp.

London, Ontario - TheNewswire - December 3, 2020 - Interest in Sernova Corp. (TSXV:SVA) (OTC:SEOVF) (FSE:PSH) is growing rapidly.

With its medical advances and latest announcements, Sernova has garnered attention in the fields of regenerative medicine, diabetes, and more recently, from the media.

News from its current clinical trials at the University of Chicago recently caught the eyes of CTV Medical Reporter Celine Zadorski, who has details:

 

Click URL to View Video: https://london.ctvnews.ca/video?clipId=2081991&jwsource=cl

How Sernova's Pouch Works:

Sernova's innovative Cell PouchTM therapeutic device - a potential cure for Type 1 Diabetes (T1D) - is a device smaller than a business card that is placed deep below a patient's skin. This in turn creates vascularized tissue chambers which then hold therapeutic cells. In just a short time, the Pouch eliminates the need for finger pricks and insulin pumps.

Sernova aims to be the company to introduce a cure for T1D and will likely see more media coverage in the months to comeand not just from medical journals. The nearly 40 million people in North America living with Diabetes are certainly receptive to learn of advancements in the field.

Clinical trials ongoing at the University of Chicago have implanted five Type 1 Diabetes patients with Sernova's Cell Pouch. The Cell Pouch with implanted cells has, in fact, been shown to release insulin and it is being measured by c-peptide, an indicator of insulin, present in patients' blood. Further, it has shown a reduction in life threatening hypoglycaemia events or episodes that diabetes patients experience, according to Delfina Siroen, Senior Director of Research at Sernova. Initial findings are promising.

Sernova researchers and team members are busy developing further medical innovations which will soon help people living with chronic diseases like haemophilia A, thyroid disease and T1D.

Sernova has been invited to share recent developments at the American Society of Transplant Surgeons 21st Annual State of the Art Winter Symposium.

Dr. Piotr Witkowski, principal investigator in Sernova's ongoing Phase I/II clinical trial on the safety and efficacy of Sernova's Cell Pouch for transplantation, will present to more than 600 transplant professionals as part of the Oral Abstract Session II on January 15, 2021.

For further details and media inquiries, please contact:

Mr. Dominic Gray
Sernova Corp
Tel: (519) 858-5126
dominic.gray@sernova.com

Forward-Looking Information

This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although TheNewswire believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward-looking statements. Forward-looking statements, are based on the beliefs, estimates and opinions on the date such statements were made. TheNewswire expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.